KONEXBiotech & Pharma390110

anymedi

₩95▲ 13.10%2026-11-18 close
Market Cap
₩900M
Turnover
₩8,586
Volume
90 shares
Shares out.
9.7M
PER
—
PBR
—
EPS
—
Dividend Yield
—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Narrower losses, but capital impairment remains

anymedi narrowed its 2025 operating and net losses, yet its total equity remains negative.

  1. 1

    On a 2025 standalone basis, revenue was 1,839 million won, operating loss 997 million won and net loss 1,172 million won, as shown in the financial statements approved at the shareholders meeting.

  2. 2

    Total equity stands at negative 524 million won, so capital impairment continues, with total assets of 4,624 million won below total liabilities of 5,149 million won.

  3. 3

    Compared with an operating loss of 2.30 billion won and a net loss of 3.13 billion won in 2024, the 2025 losses narrowed while revenue increased.

  4. 4

    On April 10, 2026, the company resolved a third-party rights offering to raise 270 million won for operating funds such as personnel costs.

  5. 5

    The company holds three new medical technology designations and two innovative medical technology designations, giving it an insurance reimbursement base, while a 2023 research report described entry barriers in non-cosmetic implants as relatively low.

02

Business structure

anymedi was founded in December 2016 by a research team from Asan Medical Center and uses AI to analyze medical imaging and 3D printing to produce patient-specific surgical tools and implants. Its core products are surgical simulators, surgical guides and custom implants.

A 2023 research report put the 2022 revenue mix at 43.2 percent implants, 25.25 percent surgical guides, 19.2 percent simulators, 7.9 percent services and 4.4 percent merchandise.

For 2024, surgical guides were the largest line at 532 million won (39.1 percent), followed by prototypes at 132 million won (9.7 percent), simulators at 79 million won (5.8 percent) and merchandise at 54 million won (4.0 percent), against total 2024 revenue of 1,360 million won.

Surgical guides are used in partial mastectomy, shoulder arthroplasty, mandibular reconstruction and orbital fracture surgery, and revenue is recognized once a hospital completes its code-in registration.

The innofit brand sells patient-specific nasal silicone and metal implants together with virtual plastic surgery software. The company cites three new medical technology designations and two innovative medical technology designations as differentiators.

The 2023 research report, however, flagged the relatively low entry barriers in non-cosmetic implants as a risk factor. The endoscopy simulator is being expanded through joint module development with endoscope manufacturers.

03

Recent trends

The disclosed results show narrowing losses alongside continued capital impairment. In 2022 revenue was 0.66 billion won and operating loss was 6.47 billion won.

In 2023 the company reported revenue of 1.12 billion won, an operating loss of 3.96 billion won and a net loss of 4.42 billion won, and in 2024 revenue of 1.36 billion won, an operating loss of 2.30 billion won and a net loss of 3.13 billion won, according to a KIND company report dated July 2025.

Net losses have continued since 2022, although the report described the size of the losses as trending lower.

According to the standalone financial statements of the 10th fiscal year approved at the regular shareholders meeting on March 31, 2026, 2025 revenue was 1,839 million won, with an operating loss of 997 million won and a net loss of 1,172 million won.

In the same statements total assets were 4,624 million won, total liabilities 5,149 million won and total equity negative 524 million won. Negative equity is the most prominent weakness in the balance sheet.

In February 2025 the company raised 1.14 billion won of short-term borrowings from IBK through a guarantee agreement with the Korea Technology Finance Corporation that carried an investment option.

A disclosure on April 10, 2026 announced a third-party rights offering to raise 270 million won for operating funds such as personnel costs. Market data shows a share price of 145 won (up 4.32 percent from the previous day), a market capitalization of 1.4 billion won and a daily trading value of 7,000 won.

Compared with a share price of 3,315 won and a market capitalization of 30.1 billion won on November 21, 2023, the scale difference is large.

04

Outlook

The outlook can be organized around two axes: whether the balance sheet improves and whether revenue growth is sustained. Losses narrowed in 2025, but an operating loss of 997 million won and negative equity exist at the same time, so capital strengthening is the priority.

The company said in its 2025 disclosure that it would pursue new borrowings alongside rights offerings, and the third-party offering in April 2026 falls within that approach.

Because the offering was only 270 million won, whether it is large enough to resolve capital impairment will become clear from future changes in total equity. On the revenue side, growth in surgical guides through expanded hospital code-ins and the ongoing U.S. clinical program are cited as drivers.

The 2023 research report explained that revenue is recognized once the code-in administrative process is complete, so the number of registered hospitals determines the pace of recognition.

Insurance reimbursement and new medical technology evaluations affect product pricing and sales, which makes the regulatory environment a key variable. The shareholders meeting on March 31, 2026 approved a stock option grant, which establishes an incentive tool for personnel.

The second-half 2023 breakeven target presented in the 2022 disclosures was not achieved, as annual operating losses continued through 2025.

05

Bull factors

Narrowing losses and higher revenue

On a 2025 standalone basis revenue rose to 1,839 million won from 1.36 billion won in 2024, while the operating loss narrowed to 997 million won from 2.30 billion won. The operating loss had been shrinking steadily from 6.47 billion won in 2022 through 2024.

The company said its cost-efficiency measures introduced in the second half of 2022 cut monthly operating costs by roughly 50 percent versus the prior level.

New medical technology and reimbursement base

The company holds three new medical technology designations, including its congenital heart simulator, and two innovative medical technology designations, and its own materials and a research report describe its insurance listings as among the largest in digital healthcare.

Both evaluation agencies rated its technology A in the 2021 technology evaluation for a KOSDAQ special listing. Clinical use is cited at over 400 breast cancer surgical guide cases, over 600 joint replacement guide cases and over 3,600 nasal implant cases.

Government-backed overseas clinical work

The company receives 2.85 billion won in support from the Ministry of Trade, Industry and Energy for 2023 to 2026 under a global cooperation program and is conducting clinical work in the United States.

The project is run together with Asan Medical Center, and a plan was announced to link local hospitals and companies to supply its heart simulator and breast cancer guide. Records of U.S. FDA and European CE clearances from 2020 are also cited.

06

Bear factors

Capital impairment

On the 2025 standalone financial statements, total equity was negative 524 million won, so capital impairment persists. Total liabilities of 5,149 million won exceed total assets of 4,624 million won.

The 1.14 billion won in short-term borrowings raised in February 2025 under a Korea Technology Finance Corporation guarantee shows reliance on external funding.

Accumulated losses and recurring fundraising

Net losses have appeared in each year from 2022 through 2025, including a net loss of 1,172 million won in 2025. A 2023 research report cited cumulative investment of about 30 billion won since the company's listing. The 270 million won rights offering in April 2026 serves mainly to cover operating costs such as personnel.

Entry barriers and the path to a KOSDAQ listing

A 2023 research report judged that entry barriers in non-cosmetic implants are relatively low and noted that revenue growth had fallen short of expectations.

After failing the KOSDAQ preliminary listing review in 2022, the company withdrew its application on April 15, and it said revenue performance was the main obstacle. The company has not yet disclosed a specific timetable for a renewed listing attempt.

07

Risk factors

Macro

Financing conditions and interest rates directly affect a company with negative equity. Because the business relies on borrowings and rights offerings, a weaker capital market could raise the cost of securing operating funds. In its 2025 disclosure the company said it would pursue new borrowings alongside rights offerings.

Industry and regulatory

Product revenue depends on new medical technology evaluations, product approvals, national insurance listings and hospital code-in procedures. Surgical guide sales only follow once the number of hospitals completing code-in grows. Regulatory changes or evaluation delays could push back the timing of revenue recognition.

Liquidity

Market data shows a daily trading value of only 7,000 won, indicating very thin trading. KONEX-listed companies generally face less frequent disclosure and more limited information flow than KOSDAQ companies. With a market capitalization of about 1.4 billion won, even small trades can produce large price swings.

08

Overall view

anymedi is a company providing AI and 3D printing based patient-specific surgical solutions, and on a 2025 standalone basis its revenue rose while operating and net losses narrowed.

Its strengths are the new medical technology and insurance listing base, the expansion of hospital code-ins and overseas clinical work supported by a government program.

Its weaknesses are negative total equity of 524 million won, reliance on borrowings and rights offerings, and four consecutive years of net losses starting in 2022. Improvement in operating indicators and weakness in the balance sheet exist at the same time.

Whether revenue growth continues alongside capital strengthening is the key variable in assessing the company. The April 2026 rights offering of 270 million won serves mainly to cover operating costs and is far from the scale needed to eliminate capital impairment.

With a daily trading value of only 7,000 won, the share price can move independently of the financial indicators. This is a qualitative summary for informational purposes.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 9 more articles and sources
  1. kind.krx.co.kr
  2. m.news.nate.com
  3. m.news.nate.com
  4. ssl.pstatic.net
  5. dailymedi.com
  6. bosa.co.kr
  7. pharmnews.com
  8. news.mt.co.kr
  9. pharmnews.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis